Gotzen 1994.

Methods	Prospective, randomized, double‐blind, placebo‐controlled study
Participants	39 participants with mild to moderate hypertension Mean age = 60 years; male (53.3%) Baseline SBP was 143.9 ± 10.3 mmHg and DBP was 85.5 ± 8.9 mmHg in placebo group Baseline SBP was 149.9 ± 15.5 mmHg and DBP was 91.1 ± 13.8 mmHg in cicletanine 100 mg group
Interventions	cicletanine 100 mg per day or placebo for 8 weeks duration cicletanine 100 mg = 20 and placebo = 19
Outcomes	Systolic blood pressure, diastolic blood pressure at end of treatment Also daytime (6.00am to 22.00pm) and nighttime (22.00pm to 6.00am) measurements
Notes	Article in German translated by Ciprian Jauca. Table II: End‐of‐treatment week 8 SBP in cicletanine 100 mg was 139.3 ± 13.5 mmHg and DBP was 85.0 ± 9.9 mmHg End‐of‐treatment week 8 SBP in placebo group was 140.3 ± 15.6 mmHg and DBP was 82.7 ± 9.8 mmHg All 39 participants completed the study (no withdrawals). Biochemical parameters were either not measured or not reported.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described in the publication.
Allocation concealment (selection bias)	Low risk	"optically identical placebo was administered double‐blind at 8:00 AM."
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not described in the publication.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study and their blood pressure measurements were reported.
Selective reporting (reporting bias)	High risk	Adverse events and biochemical markers were not reported.
Other bias	Unclear risk	The authors did not declare sponsorship or funding of this study and conflicts of interest in the publication.